BofA raises Ascendis Pharma price target to $216, affirms buy rating

From Yahoo Finance: 2025-06-16 10:50:00

Ascendis Pharma A/S (NASDAQ:ASND) is considered one of the best 52-week high stocks to buy, with BofA analyst Tazeen Ahmad raising the price target to $216 from $201. This adjustment follows positive interim results from the Phase 2 COACH trial, showing significant annualized growth velocity benefits in children with Achondroplasia (ACH) with a combination treatment. The trial results are expected to strengthen Ascendis’s market position, with plans to release 52-week data in the fourth quarter. Additionally, the FDA has accepted the company’s New Drug Application for TransCon, a candidate drug for treating achondroplasia. The company specializes in developing and commercializing therapies for unmet medical needs, focusing on endocrinology and oncology using a proprietary TransCon technology platform. While Ascendis Pharma shows promise as an investment, some believe that certain AI stocks offer greater potential upside and lower downside risk. For those seeking an undervalued AI stock, a free report on the best short-term AI stock is available.



Read more at Yahoo Finance: BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating